Related Experiment Video
Updated: Jul 17, 2026
09:11
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Histone deacetylase inhibitors in APL and beyond
K Petrie1, N Prodromou, A Zelent
1Section of Haemato-Oncology, Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London SW3 6JB, UK.
Current Topics in Microbiology and Immunology
|January 16, 2007
Summary
Histone deacetylase inhibitors are crucial in cancer research for targeting epigenetic alterations. This chapter reviews their role in APL, combination therapies, and clinical trials.
Area of Science:
- Epigenetics and Cancer Research
- Chromatin Modifications
Background:
- Epigenetic patterns are vital in cellular processes and cancer progression.
- Disruptions in epigenetic markers can act as cancer biomarkers.
- Histone deacetylases (HDACs) are key enzymes in epigenetic regulation.
Purpose of the Study:
- To provide an overview of Class I and II histone deacetylases.
- To guide on diverse histone deacetylase inhibitors (HDACi) and their activities in Acute Promyelocytic Leukemia (APL).
- To discuss the rationale for using HDAC inhibitors in combination cancer therapy and their clinical trial status.
Main Methods:
- Review of scientific literature on HDACs and HDAC inhibitors.
- Analysis of HDAC inhibitor activities specifically within the context of APL.
- Examination of clinical trial data for HDAC inhibitors in cancer treatment.
Main Results:
- Overview of Class I and II HDACs presented.
- Diverse types of HDAC inhibitors and their activities in APL detailed.
- Rationale for combination therapy and current clinical trial status discussed.
Conclusions:
- HDAC inhibitors represent a significant area of research and development in cancer therapy.
- Understanding HDACs and their inhibitors is critical for advancing cancer treatment strategies.
- Combination therapies involving HDAC inhibitors show promise for cancer treatment.
Related Concept Videos
00:50Anaphase Promoting Complex
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
01:32Chromatin Modification in iPS Cells
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
02:25Spreading of Chromatin Modifications
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer is an enzyme that can...
Writers
The writer is an enzyme that can...
02:32Histone Modification
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
02:32Histone Modification
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...